Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Non Operating Income (2022 - 2025)

Oramed Pharmaceuticals' Non Operating Income history spans 4 years, with the latest figure at $85.6 million for Q4 2025.

  • For Q4 2025, Non Operating Income changed N/A year-over-year to $85.6 million; the TTM value through Dec 2025 reached $158.8 million, changed N/A, while the annual FY2025 figure was $89.5 million, 4013.12% up from the prior year.
  • Non Operating Income reached $85.6 million in Q4 2025 per ORMP's latest filing, up from $61.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $85.6 million in Q4 2025 to a low of -$15.4 million in Q3 2024.
  • Average Non Operating Income over 4 years is $12.6 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: plummeted 3644.83% in 2024, then skyrocketed 498.64% in 2025.
  • A 4-year view of Non Operating Income shows it stood at $1.0 million in 2022, then tumbled by 547.88% to -$4.5 million in 2023, then tumbled by 242.92% to -$15.4 million in 2024, then skyrocketed by 654.81% to $85.6 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Non Operating Income are $85.6 million (Q4 2025), $61.5 million (Q3 2025), and $15.4 million (Q2 2025).